Advertisement

Current Allergy and Asthma Reports

, Volume 8, Issue 4, pp 277–287 | Cite as

Immunomodulatory approaches to the management of chronic urticaria: An immune-mediated inflammatory disease

  • Clifton O. BinghamIII
Article

Abstract

Although commonly encountered in clinical practice, chronic urticaria (CU) remains difficult to treat. In contrast to acute urticaria, neither exogenous triggers nor specific immunoglobulin E are identified in most chronic cases. A body of evidence suggests that CU is represented within the spectrum of immune-mediated inflammatory diseases (IMID). Our understanding of the CU disease pathogenesis now recognizes a role for T cells, B cells, and autoantibodies, and intrinsic abnormalities of histamine-releasing effector cells, thus providing new targets of intervention beyond the current mainstay of often inadequate symptomatic treatment directed against histamine receptors and steroids, with their attendant morbidities. Agents previously used to treat other autoimmune and inflammatory diseases have demonstrated efficacy in CU. Newer biologic and nonbiologic immunomodulatory agents approved for other indications and in clinical development provide potential options for this often severe disease.

Keywords

Mast Cell Urticaria Allergy Clin Immunol Abatacept Omalizumab 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References and Recommended Reading

  1. 1.
    Grob JJ, Revuz J, Ortonne JP, et al.: Comparative study of the impact of chronic urticaria, psoriasis and atopic dermatitis on the quality of life. Br J Dermatol 2005, 152:289–295.PubMedCrossRefGoogle Scholar
  2. 2.
    Delong LK, Culler SD, Saini SS, et al.: Annual direct and indirect health care costs of chronic idiopathic urticaria: a cost analysis of 50 nonimmunosuppressed patients. Arch Dermatol 2008, 144:35–39.PubMedCrossRefGoogle Scholar
  3. 3.
    Di Lorenzo G, Pacor ML, Mansueto P, et al.: Is there a role for antileukotrienes in urticaria? Clin Exp Dermatol 2006, 31:327–334.PubMedCrossRefGoogle Scholar
  4. 4.
    Powell RJ, Du Toit GL, Siddique N, et al.: BSACI guidelines for the management of chronic urticaria and angio-oedema. Clin Exp Allergy 2007, 37:631–650.PubMedCrossRefGoogle Scholar
  5. 5.
    Doutre MS: Chronic urticaria and thyroid auto-immunity. Clin Rev Allergy Immunol 2006, 30:31–37.PubMedCrossRefGoogle Scholar
  6. 6.
    O’Donnell BF, O’Neill CM, Francis DM, et al.: Human leucocyte antigen class II associations in chronic idiopathic urticaria. Br J Dermatol 1999, 140:853–858.PubMedCrossRefGoogle Scholar
  7. 7.
    Marsland AM: Autoimmunity and complement in the pathogenesis of chronic urticaria. Curr Allergy Asthma Rep 2006, 6:265–269.PubMedCrossRefGoogle Scholar
  8. 8.
    Puccetti A, Bason C, Simeoni S, et al.: In chronic idiopathic urticaria autoantibodies against Fc epsilonRII/CD23 induce histamine release via eosinophil activation. Clin Exp Allergy 2005, 35:1599–1607.PubMedCrossRefGoogle Scholar
  9. 9.
    Vasagar K, Vonakis BM, Gober LM, et al.: Evidence of in vivo basophil activation in chronic idiopathic urticaria. Clin Exp Allergy 2006, 36:770–776.PubMedCrossRefGoogle Scholar
  10. 10.
    Eckman JA, Hamilton RG, Gober LM, et al.: Basophil phenotypes in chronic idiopathic urticaria in relation to disease activity and autoantibodies. J Invest Dermatol 2008 (Epub ahead of print).Google Scholar
  11. 11.
    Vonakis BM, Saini SS: Basophils and mast cells in chronic idiopathic urticaria. Curr Allergy Asthma Rep 2005, 5:270–276.PubMedCrossRefGoogle Scholar
  12. 12.
    Caproni M, Giomi B, Volpi W, et al.: Chronic idiopathic urticaria: infiltrating cells and related cytokines in autologous serum-induced wheals. Clin Immunol 2005, 114:284–292.PubMedCrossRefGoogle Scholar
  13. 13.
    Kuek A, Hazleman BL, Ostor AJ: Immune-mediated inflammatory diseases (IMIDs) and biologic therapy: a medical revolution. Postgrad Med J 2007, 83:251–260.PubMedCrossRefGoogle Scholar
  14. 14.
    Brightling C, Berry M, Amrani Y: Targeting TNF-alpha: a novel therapeutic approach for asthma. J Allergy Clin Immunol 2008, 121:5–10.PubMedCrossRefGoogle Scholar
  15. 15.
    Bach JF: Infections and autoimmune diseases. J Autoimmun 2005, 25(Suppl):74–80.PubMedCrossRefGoogle Scholar
  16. 16.
    Haas N, Iwen W, Grabbe J, et al.: MHC class II antigen expression is increased in different forms of urticaria. Int Arch Allergy Immunol 1996, 109:177–182.PubMedCrossRefGoogle Scholar
  17. 17.
    Pacor ML, Di Lorenzo G, Mansueto P, et al.: Relationship between human leucocyte antigen class I and class II and chronic idiopathic urticaria associated with aspirin and/or NSAIDs hypersensitivity. Mediators Inflamm 2006, 2006:62489.Google Scholar
  18. 18.
    Ying S, Kikuchi Y, Meng Q, et al.: TH1/TH2 cytokines and inflammatory cells in skin biopsy specimens from patients with chronic idiopathic urticaria: comparison with the allergen-induced late-phase cutaneous reaction. J Allergy Clin Immunol 2002, 109:694–700.PubMedCrossRefGoogle Scholar
  19. 19.
    Garmendia JV, Zabaleta M, Aldrey O, et al.: Immunophenotype characteristics of peripheral blood mononuclear leukocytes of chronic idiopathic urticaria patients. Invest Clin 2006, 47:361–369.PubMedGoogle Scholar
  20. 20.
    Toubi E, Adir-Shani A, Kessel A, et al.: Immune aberrations in B and T lymphocytes derived from chronic urticaria patients. J Clin Immunol 2000, 20:371–378.PubMedCrossRefGoogle Scholar
  21. 21.
    Grammer LC, Shaughnessy MA, Harris KE, et al.: Lymphocyte subsets and activation markers in patients with acute episodes of idiopathic anaphylaxis. Ann Allergy Asthma Immunol 2000, 85:368–371.PubMedGoogle Scholar
  22. 22.
    Oskeritzian CA, Zhao W, Min HK, et al.: Surface CD88 functionally distinguishes the MCTC from the MCT type of human lung mast cell. J Allergy Clin Immunol 2005, 115:1162–1168.PubMedCrossRefGoogle Scholar
  23. 23.
    Yasnowsky KM, Dreskin SC, Efaw B, et al.: Chronic urticaria sera increase basophil CD203c expression. J Allergy Clin Immunol 2006, 117:1430–1434.PubMedCrossRefGoogle Scholar
  24. 24.
    Lourenco FD, Azor MH, Santos JC, et al.: Activated status of basophils in chronic urticaria leads to interleukin-3 hyper-responsiveness and enhancement of histamine release induced by anti-IgE stimulus. Br J Dermatol 2008 (Epub ahead of print).Google Scholar
  25. 25.
    Vonakis BM, Vasagar K, Gibbons SP Jr, et al.: Basophil FcepsilonRI histamine release parallels expression of Src-homology 2-containing inositol phosphatases in chronic idiopathic urticaria. J Allergy Clin Immunol 2007, 119:441–448.PubMedCrossRefGoogle Scholar
  26. 26.
    Sabroe RA, Poon E, Orchard GE, et al.: Cutaneous inflammatory cell infiltrate in chronic idiopathic urticaria: comparison of patients with and without anti-FcepsilonRI or anti-IgE autoantibodies. J Allergy Clin Immunol 1999, 103:484–493.PubMedCrossRefGoogle Scholar
  27. 27.
    Staumont-Salle D, Dombrowicz D, Capron M, et al.: Eosinophils and urticaria. Clin Rev Allergy Immunol 2006, 30:13–18.PubMedCrossRefGoogle Scholar
  28. 28.
    Caproni M, Giomi B, Melani L, et al.: Cellular infiltrate and related cytokines, chemokines, chemokine receptors and adhesion molecules in chronic autoimmune urticaria: comparison between spontaneous and autologous serum skin test induced wheal. Int J Immunopathol Pharmacol 2006, 19:507–515.PubMedGoogle Scholar
  29. 29.
    Kyburz D, Brentano F, Gay S: Mode of action of hydroxychloroquine in RA-evidence of an inhibitory effect on toll-like receptor signaling. Nat Clin Pract Rheumatol 2006, 2:458–459.PubMedCrossRefGoogle Scholar
  30. 30.
    Nosal R, Drabikova K, Pecivova J: Effect of chloroquine on isolated mast cells. Agents Actions 1991, 33:37–40.PubMedCrossRefGoogle Scholar
  31. 31.
    Reeves GE, Boyle MJ, Bonfield J, et al.: Impact of hydroxychloroquine therapy on chronic urticaria: chronic autoimmune urticaria study and evaluation. Intern Med J 2004, 34:182–186.PubMedCrossRefGoogle Scholar
  32. 32.
    Harrison CA, Bastan R, Peirce MJ, et al.: Role of calcineurin in the regulation of human lung mast cell and basophil function by cyclosporine and FK506. Br J Pharmacol 2007, 150:509–518.PubMedCrossRefGoogle Scholar
  33. 33.
    Grattan CE, O’Donnell BF, Francis DM, et al.: Randomized double-blind study of cyclosporin in chronic ‘idiopathic’ urticaria. Br J Dermatol 2000, 143:365–372.PubMedCrossRefGoogle Scholar
  34. 34.
    Vena GA, Cassano N, Colombo D, et al.: Cyclosporine in chronic idiopathic urticaria: a double-blind, randomized, placebo-controlled trial. J Am Acad Dermatol 2006, 55:705–709.PubMedCrossRefGoogle Scholar
  35. 35.
    Kessel A, Bamberger E, Toubi E: Tacrolimus in the treatment of severe chronic idiopathic urticaria: an open-label prospective study. J Am Acad Dermatol 2005, 52:145–148.PubMedCrossRefGoogle Scholar
  36. 36.
    Shahar E, Bergman R, Guttman-Yassky E, et al.: Treatment of severe chronic idiopathic urticaria with oral mycophenolate mofetil in patients not responding to antihistamines and/or corticosteroids. Int J Dermatol 2006, 45:1224–1227.PubMedCrossRefGoogle Scholar
  37. 37.
    Moder KG: Mycophenolate mofetil: new applications for this immunosuppressant. Ann Allergy Asthma Immunol 2003, 90:15–19.PubMedGoogle Scholar
  38. 38.
    Clunie GP, Lennard L: Relevance of thiopurine methyltransferase status in rheumatology patients receiving azathioprine. Rheumatology (Oxford) 2004, 43:13–18.CrossRefGoogle Scholar
  39. 39.
    Malaviya R, Uckun FM: Leflunomide metabolite analogue alpha-cyano-beta-hydroxy-beta-methyl-N-[3-(trifluoromet hyl)phenyl]propenam ide inhibits IgE/FcepsilonRI receptormediated mast cell leukotriene release and allergic asthma in mice. Am J Ther 2001, 8:309–316.PubMedCrossRefGoogle Scholar
  40. 40.
    Sawamukai N, Saito K, Yamaoka K, et al.: Leflunomide inhibits PDK1/Akt pathway and induces apoptosis of human mast cells. J Immunol 2007, 179:6479–6484.PubMedGoogle Scholar
  41. 41.
    Vincenti F, Larsen C, Durrbach A, et al.: Costimulation blockade with belatacept in renal transplantation. N Engl J Med 2005, 353:770–781.PubMedCrossRefGoogle Scholar
  42. 42.
    Chamian F, Lowes MA, Lin SL, et al.: Alefacept reduces infiltrating T cells, activated dendritic cells, and inflammatory genes in psoriasis vulgaris. Proc Natl Acad Sci U S A 2005, 102:2075–2080.PubMedCrossRefGoogle Scholar
  43. 43.
    St Clair EW, Tedder TF: New prospects for autoimmune disease therapy: B cells on deathwatch. Arthritis Rheum 2006, 54:1–9.PubMedCrossRefGoogle Scholar
  44. 44.
    Levesque MC, St Clair EW: B cell-directed therapies for autoimmune disease and correlates of disease response and relapse. J Allergy Clin Immunol 2008, 121:13–21.PubMedCrossRefGoogle Scholar
  45. 45.
    Joly P, Mouquet H, Roujeau JC, et al.: A single cycle of rituximab for the treatment of severe pemphigus. N Engl J Med 2007, 357:545–552.PubMedCrossRefGoogle Scholar
  46. 46.
    Simon D, Hosli S, Kostylina G, et al.: Anti-CD20 (rituximab) treatment improves atopic eczema. J Allergy Clin Immunol 2008, 121:122–128.PubMedCrossRefGoogle Scholar
  47. 47.
    Looney RJ, Srinivasan R, Calabrese LH: The effects of rituximab on immunocompetency in patients with autoimmune disease. Arthritis Rheum 2008, 58:5–14.PubMedCrossRefGoogle Scholar
  48. 48.
    Boyce JA: Successful treatment of cold-induced urticaria/anaphylaxis with anti-IgE. J Allergy Clin Immunol 2006, 117:1415–1418.PubMedCrossRefGoogle Scholar
  49. 49.
    Metz M, Bergmann P, Zuberbier T, et al.: Successful treatment of cholinergic urticaria with anti-immunoglobulin E therapy. Allergy 2008, 63:247–249.PubMedGoogle Scholar
  50. 50.
    Spector SL, Tan RA: Effect of omalizumab on patients with chronic urticaria. Ann Allergy Asthma Immunol 2007, 99:190–193.PubMedCrossRefGoogle Scholar
  51. 51.
    Sands MF, Blume JW, Schwartz SA: Successful treatment of 3 patients with recurrent idiopathic angioedema with omalizumab. J Allergy Clin Immunol 2007, 120:979–981.PubMedCrossRefGoogle Scholar
  52. 52.
    Noga O, Hanf G, Brachmann I, et al.: Effect of omalizumab treatment on peripheral eosinophil and T-lymphocyte function in patients with allergic asthma. J Allergy Clin Immunol 2006, 117:1493–1499.PubMedCrossRefGoogle Scholar
  53. 53.
    Cassano N, D’Argento V, Filotico R, et al.: Low-dose dapsone in chronic idiopathic urticaria: preliminary results of an open study. Acta Derm Venereol 2005, 85:254–255.PubMedGoogle Scholar
  54. 54.
    Engin B, Ozdemir M: Prospective randomized non-blinded clinical trial on the use of dapsone plus antihistamine vs. antihistamine in patients with chronic idiopathic urticaria. J Eur Acad Dermatol Venereol 2008, 22:481–486.PubMedCrossRefGoogle Scholar
  55. 55.
    Baccarani M, Cilloni D, Rondoni M, et al.: The efficacy of imatinib mesylate in patients with FIP1L1-PDGFRalpha-positive hypereosinophilic syndrome. Results of a multicenter prospective study. Haematologica 2007, 92:1173–1179.PubMedCrossRefGoogle Scholar
  56. 56.
    Juurikivi A, Sandler C, Lindstedt KA, et al.: Inhibition of c-kit tyrosine kinase by imatinib mesylate induces apoptosis in mast cells in rheumatoid synovia: a potential approach to the treatment of arthritis. Ann Rheum Dis 2005, 64:1126–1131.PubMedCrossRefGoogle Scholar
  57. 57.
    Rothenberg ME, Klion AD, Roufosse FE, et al.: Treatment of patients with the hypereosinophilic syndrome with mepolizumab. N Engl J Med 2008, 358:1215–1228.PubMedCrossRefGoogle Scholar
  58. 58.
    Magerl M, Philipp S, Manasterski M, et al.: Successful treatment of delayed pressure urticaria with anti-TNFalpha. J Allergy Clin Immunol 2007, 119:752–754.PubMedCrossRefGoogle Scholar
  59. 59.
    Goldbach-Mansky R, Dailey NJ, Canna SW, et al.: Neonatal-onset multisystem inflammatory disease responsive to interleukin-1beta inhibition. N Engl J Med 2006, 355:581–592.PubMedCrossRefGoogle Scholar
  60. 60.
    Gabay C: Interleukin-6 and chronic inflammation. Arthritis Res Ther 2006, 8(Suppl 2):S3.PubMedCrossRefGoogle Scholar
  61. 61.
    Smolen JS, Beaulieu A, Rubbert-Roth A, et al.: Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial. Lancet 2008, 371:987–997.PubMedCrossRefGoogle Scholar
  62. 62.
    McGirt LY, Vasagar K, Gober LM, et al.: Successful treatment of recalcitrant chronic idiopathic urticaria with sulfasalazine. Arch Dermatol 2006, 142:1337–1342.PubMedCrossRefGoogle Scholar
  63. 63.
    Tian H, Cronstein BN: Understanding the mechanisms of action of methotrexate: implications for the treatment of rheumatoid arthritis. Bull NYU Hosp Jt Dis 2007, 65:168–173.PubMedGoogle Scholar
  64. 64.
    Gach JE, Sabroe RA, Greaves MW, et al.: Methotrexateresponsive chronic idiopathic urticaria: a report of two cases. Br J Dermatol 2001, 145:340–343.PubMedCrossRefGoogle Scholar
  65. 65.
    Godse K: Methotrexate in autoimmune urticaria. Indian J Dermatol Venereol Leprol 2004, 70:377.PubMedGoogle Scholar
  66. 66.
    Pavy S, Constantin A, Pham T, et al.: Methotrexate therapy for rheumatoid arthritis: clinical practice guidelines based on published evidence and expert opinion. Joint Bone Spine 2006, 73:388–395.PubMedCrossRefGoogle Scholar
  67. 67.
    Rudick RA, Stuart WH, Calabresi PA, et al.: Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Engl J Med 2006, 354:911–923.PubMedCrossRefGoogle Scholar
  68. 68.
    Sandborn WJ, Colombel JF, Enns R, et al.: Natalizumab induction and maintenance therapy for Crohn’s disease. N Engl J Med 2005, 353:1912–1925.PubMedCrossRefGoogle Scholar
  69. 69.
    Khalili K, White MK, Lublin F, et al.: Reactivation of JC virus and development of PML in patients with multiple sclerosis. Neurology 2007, 68:985–990.PubMedCrossRefGoogle Scholar
  70. 70.
    O’Dell JR: Therapeutic strategies for rheumatoid arthritis. N Engl J Med 2004, 350:2591–2602.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2008

Authors and Affiliations

  1. 1.Divisions of Rheumatology and Allergy and Clinical Immunology, Department of MedicineJohns Hopkins UniversityBaltimoreUSA

Personalised recommendations